February 29, 2024 (press release) –
GAITHERSBURG, Md., Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44th Annual Health Care Conference.
Conference Details: |
||||||
Fireside Chat |
||||||
Date: |
Wednesday, March 6, 2024 |
|||||
Time: |
1:30 – 2:00 p.m. Eastern Standard Time (EST) |
|||||
Location: |
Boston Marriott Copley Place in Boston, Massachusetts |
|||||
Moderator: |
Brendan Smith, Ph.D., Vice President, Biotechnology Equity Research |
|||||
Novavax participant: |
John Jacobs, President and Chief Executive Officer |
|||||
Conference |
||||||
Event: |
Investor Meetings |
|||||
Date: |
Wednesday, March 6, 2024 |
|||||
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes a vaccine for COVID-19 and influenza combined. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
SOURCE Novavax, Inc.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistribute or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.